Breaking News, Financial News

Novo Nordisk’s YTD Revenues up 23%

GLP-1 diabetes sales grow 25% and Obesity care grows by 44%.

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk
For the period January 1, 2024 to September 30, 2024.
YTD Revenues: $30.6 billion (+23%)
YTD Earnings: $10.9 billion (+18%)  
Comments: Sales within Diabetes and Obesity care increased by 25% to $28.7 billion, mainly driven by GLP-1 diabetes sales growth of 25% and Obesity care growing by 44%. Rare disease sales increased by 3% to $1.9 billion. Ozempic sales were up 32% to $12.9 billion. Wegovy sales were up 76% to $5.7 billion. Sales in North America increased by 31% and International Operations increased by 13%.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters